A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
← catalyst calendarNCT06265727 · readout in 150 d
Sponsored by Corbus Pharmaceuticals Inc. (industry) · CRBP — their whole pipeline →. With CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
348estimated
Sites
41
Countries
France, Italy, Moldova +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-01 | actual | When the study began enrolling |
| Primary completion | 2027-01-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-27 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor, Adult
Interventions
- Drug: CRB-701
- Drug: Anti-PD-1
Primary outcomes
what the primary-completion date above is the date OFPart A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701
measured 21 days
Part B & C: To evaluate efficacy in terms of Objective Response Rate (ORR)
measured Up to 6 months
Permalink · CRBP's whole pipeline · Catalyst calendar · Every registered study · What changed